Cargando…
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
Autores principales: | Rocha, C R R, Garcia, C C M, Vieira, D B, Quinet, A, de Andrade-Lima, L C, Munford, V, Belizário, J E, Menck, C F M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650535/ https://www.ncbi.nlm.nih.gov/pubmed/25880094 http://dx.doi.org/10.1038/cddis.2015.101 |
Ejemplares similares
-
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
por: Rocha, C R R, et al.
Publicado: (2014) -
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
por: Rocha, Clarissa Ribeiro Reily, et al.
Publicado: (2016) -
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2018) -
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2009) -
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2009)